Pfizer Issues RFP for Artificial Intelligence/Machine Learning Research in Hemophilia

Pfizer has issued an RPF for Artificial Intelligence/Machine Learning Research in Hemophilia.

The RFP seeks projects dedicated to Artificial Intelligence/Machine Learning, including research studies that advance artificial intelligence/machine learning methods, tools, and/or apps for application on patient data with respect to, for example, infusions, bleeds, laboratory factors, and lifestyle (a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred); research studies that develop AI/ML methods and tools that increase the ability to predict disease risk, identify disease severity and progression due to morbidity from joint disease or recurrent bleeding, and/or improve disease management for persons with hemophilia (PWH), including optimizing treatment for patients with high-bleeding risk (e.g., severe hemophilia); research projects that develop AI/ML methods and tools that enhance patient engagement with the local hemophilia treatment center and maximize follow-up after potential one-time treatments such as gene therapy, including for patients living in remote or geographically distant areas; research projects that develop intelligent educational tools and platforms that leverage the power of AI/ML to deliver innovative educational and training programs for patients, caregivers, clinicians, healthcare providers, researchers, regulatory agencies, and policy makers (a focus on emerging potential one-time treatments such as genetic medicine/gene transfer is strongly preferred); research studies that leverage AI/ML to enhance data surveillance and increase collaboration among data partners and the ability to collect PWH-related data in real time and that link useful real world data from diverse sources (e.g., claims, EHR, registry, patient-reported outcomes, patient-level channels such as wearable devices, mobile apps, sensors); and/or the development of a recommendation system that leverages AI-NLP approach and published literature and scientific evidence to offer more personalized guidelines and algorithms with respect to monitoring adherence and outcomes.

Projects with a focus on emerging potential one-time treatments such as genetic medicine/gene transfer will receive preference. Projects requesting up to $450,000 will be considered, and Pfizer anticipates awarding a single grant.

To be eligible, the institution and principal investigator must be based in the United States.

See the Pfizer website for complete program guidelines and application instructions.

View another RFP related to medical research

Deadline: July 10, 2020